A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate

European Journal of Neurology

Volumn 14, Issue 11, 2007, Pages 1266-1274

  Debouverie, M ^a,b   Moreau, T ^c   Lebrun, C ^d   Heinzlef, O ^e   Brudon, F ^f   Msihid, J ^g  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c HÔPITAL DU BOCAGE   (France)

^d PASTEUR HOSPITAL   (France)

^e CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^f Clinique du Tonkin   (France)

^g GECEM   (France)

Author keywords

interferon; Glatiramer acetate; Immunomodulatory treatment; Observational study; Relapsing remitting multiple sclerosis; Treatment switch

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 35448970646     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01964.x     Document Type: Article

References (21)

1. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002 16:825 850.
2. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001 56:702 708.
3. Ziemssen T, Kumpfel T, Schneider H, Klinkert WE, Neuhaus O, Hohlfeld R. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: implications for multiple sclerosis therapy. Journal of the Neurological Sciences 2005 233:109 112.
4. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurology 2005 4:567 575.
5. Bornstein Mb, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New England Journal of Medicine 1987 317:408 414.
6. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Annals of Neurology 2001 49:290 297.
7. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 45:1268 1276.
8. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 2001 57:731 733.
9. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Multiple Sclerosis 2006 12:309 320.
10. Carra A, Onaha P, Sinay V et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. European Journal of Neurology 2003 10:671 676.
11. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology 2005 12:425 431.
12. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Multiple Sclerosis 2001 7:349 353.
13. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. European Journal of Neurology 2006 13:471 474.
14. Vallittu AM, Peltoniemi J, Elovaara I et al. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurologica Scandinavica 2005 112:234 237.
15. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurologica Scandinavica 2006 113:378 386.
16. Heinzlef O, Moreau T. Acétate de glatiramère: Expérience française dans le cadre de l'ATU. Neurologies 2005 5:432 436.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33:1444 1452.
18. Martinelli Boneschi F, Rovaris M, Johnson KP et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis 2003 9:349 355.
19. Pittock SJ, Mayr WT, Mcclelland Rl et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004 62:51 59.
20. Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2002 16:563 578.
21. Sørensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. European Journal of Neurology 2005 12:817 827.